High daily insulin exposure in patients with type 2 diabetes isassociated with increased risk of cardiovascular events

Atherosclerosis

Volumn 240, Issue 2, 2015, Pages 318-323

  Stoekenbroek, R M ^a   Rensing, K L ^a   Bernelot Moens, S J ^a   Nieuwdorp, M ^a   DeVries, J H ^a   Zwinderman, A H ^a   Stroes, E S ^a   Currie, C J ^b   Hutten, B A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes; Insulin therapy

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; METFORMIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; SEX; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926512788     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.040     Document Type: Article

References (30)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N.Engl. J. Med. 1998, 339:229-234.
2. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004, 141:421-431.
3. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N.Engl. J. Med. 2008, 358:2545-2559.
4. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N.Engl. J. Med. 2008, 358:2560-2572.
5. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N.Engl. J. Med. 2009, 360:129-139.
6. Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N.Engl. J. Med. 2012, 367:319-328.
7. Riddle M.C., Ambrosius W.T., Brillon D.J., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010, 33:983-990.
8. Bonds D.E., Miller M.E., Bergenstal R.M., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340. b4909-b4909.
9. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N.Engl. J. Med. 2008, 359:1577-1589.
10. Hoebers L.P., Claessen B.E., Woudstra P., DeVries J.H., Wykrzykowska J.J., Vis M.M., et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. Eurointervention 2014, 10:90-96.
11. Anselmino M., Ohrvik J., Malmberg K., Standl E., Ryden L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the euro heart survey on diabetes and the Heart. Eur. Heart J. 2008, 29:177-184.
12. Smooke S., Horwich T.B., Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am. Heart J. 2005, 149:168-174.
13. Margolis D.J., Hoffstad O., Strom B.L. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol. Drug Saf. 2008, 17:753-759.
14. Colayco D.C., Niu F., McCombs J.S., Cheetham T.C. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011, 34:77-83.
15. Gamble J.M., Simpson S.H., Eurich D.T., Majumdar S.R., Johnson J.A. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes. Metab. 2010, 12:47-53.
16. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
17. Rensing K.L., Reuwer A.Q., Arsenault B.J., von der Thusen J.H., Hoekstra J.B., Kastelein J.J., et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes Obes. Metab. 2011, 13:1073-1087.
18. Park Y.M., Kashyap R., Major A., Silverstein R.L. Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis. Lab. Invest. 2012, 92:1171-1180.
19. Muntoni S., Muntoni S., Draznin B. Effects of chronic hyperinsulinemia in insulin-resistant patients. Curr. Diabetes Rep. 2008, 8:233-238.
20. Chaudhuri A., Dandona P., Fonseca V. Cardiovascular benefits of exogenous insulin. J.Clin. Endocrinol. Metab. 2012, 97:3079-3091.
21. Paneni F., Beckman J.A., Creager M.A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur. Heart J. 2013, 34:2436-2443.
22. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J.Exp. Med. 2008, 205:2409-2417.
23. Eeg-Olofsson K., Cederholm J., Nilsson P.M., et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J.Intern. Med. 2010, 268:471-482.
24. Zoungas S., Chalmers J., Ninomiya T., et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012, 55:636-643.
25. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
26. Kramer C.K., Zinman B., Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013, 1:28-34.
27. Hemmingsen B., Christensen L.L., Wetterslev J., et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012, 344:e1771.
28. Goudswaard A.N., Furlong N.J., Valk G.D., Stolk R.P., Rutten G.E.H.M. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2004, (4). Art. No.: CD003418. 10.1002/14651858.CD003418.pub2.
29. Kooy A., De Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 2009, 169:616-625.
30. Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl.1):S5-S13.